Business Details
Early Detection of Heart Disease Through Advanced CIMT Testing
Cardiorisk Ultrasound is a world-class service company dedicated to the early detection and monitoring of cardiovascular disease, the leading cause of morbidity and mortality in the Americas and Europe. We provide medical communities with non-invasive, cost-effective products and services designed to identify and reduce the incidence of heart attacks, strokes, and other ischemic events. Our proprietary ultrasound image scanning and processing utilize FDA-cleared equipment, patented software, and a nationally recognized screening protocol. Our team maintains the highest professional and ethical standards, validated through rigorous scientific methodologies and quality controls. By offering services directly at physicians' offices or local clinics, we maximize efficiency while minimizing variability and operational costs.Our sonographers are trained to the highest standards, ensuring consistent, reproducible results within 15-minute patient sessions. We provide comprehensive support including equipment, software, patient materials, and physician training, requiring no capital investment from medical practices. With a focus on innovation and quality, CardioRisk has become the gold standard for cardiovascular risk assessment, supported by peer-reviewed studies demonstrating 98.6% accuracy in detecting cardiovascular events before they occur. Our leadership team combines decades of medical, epidemiological, and business expertise to advance cardiovascular health solutions. We maintain partnerships with major insurance providers and adhere to FDA regulations, ensuring accessible, reliable testing for at-risk patient populations.
Services
CIMT Testing
Ultrasound Scanning
Cardiovascular Monitoring
Medical Imaging Services
Risk Assessment Programs
Physician Training
Diagnostic Reporting
Preventive Cardiology
Arterial Health Screening
Plaque Detection
Highlights and features
- We offer FDA-cleared non-invasive cardiovascular testing with 98.6% accuracy
- Our patented protocols ensure consistent, reproducible results across all locations
- We provide comprehensive turnkey solutions with no equipment investment required
- Our sonographers undergo rigorous biannual validation by University of Utah biostatisticians
- We deliver results within 10 business days with physician interpretation guides
What people say
Reliable reports
Life-saving technology
Highly accurate readings
Non-invasive procedure
Expert interpretation
Services
CIMT Testing
Carotid Intima Media Thickness (CIMT) testing measures arterial wall thickness to detect plaque buildup. This non-invasive ultrasound identifies cardiovascular risks before symptoms appear. Backed by 10-year clinical studies showing 98.6% accuracy in predicting heart attacks and strokes, our protocol uses FDA-cleared equipment and patented software for precise measurements.
Ultrasound Scanning
Our B-mode ultrasound technology captures high-resolution carotid artery images. Trained sonographers complete scans in under 15 minutes using standardized protocols. The procedure isolates the intima-media layers to assess atherosclerotic burden without radiation exposure. Results include detailed reports with patient and physician copies for informed decision-making.
Risk Assessment
We provide comprehensive cardiovascular risk evaluation through IMT measurements. Our service identifies soft plaque accumulation missed by traditional tests like stress echos and EBCT. The assessment helps physicians determine patients' risk levels for ischemic events, offering critical insights for intermediate-risk patients with normal cholesterol levels.
Physician Support
We offer complete turnkey solutions including equipment, trained personnel, and interpretation services. Our support package features billing assistance, patient education materials, and best practices documentation. Physicians receive test results within 10 business days with interpretation guides and participate in free web conferences for clinical training.
Preventive Cardiology
Our preventive approach detects early-stage atherosclerosis before acute events occur. By identifying arterial inflammation and plaque size, we enable proactive treatment adjustments. The service helps physicians implement precision medicine protocols that have been shown to halt and reverse cardiovascular disease progression in clinical studies.
People
Todd Eldredge
Chief Executive Officer
Dr. Todd Eldredge has 20+ years of medical industry experience with expertise in cardiovascular epidemiology. He holds a PhD, MBA, and MPH, and authored international best-selling books on cardiovascular wellness. Previously held executive roles at pharmaceutical companies and medical startups.
Ken Brigham
Vice President
Ken Brigham leads global sales with a track record of growing businesses from $1M to $100M+ in revenue. Former executive at Rhone-Poulenc and Sanofi Pasteur, where he increased sales by 200-300%. Joined CardioRisk after personal experience with their lifesaving technology.
Dr. Amy Doneen
Medical Consultant
Dr. Amy Doneen co-founded the BaleDoneen Method for cardiovascular prevention. As a nurse practitioner and precision medicine expert, she runs a clinic with a written guarantee of arterial wellness. Her approach has been proven to reverse cardiovascular disease in peer-reviewed studies.
Questions
What does CIMT testing detect?
CIMT testing detects arterial plaque buildup by measuring carotid artery wall thickness. This identifies cardiovascular disease risk before heart attacks or strokes occur, catching 98.6% of events in clinical studies.
How does the testing process work?
A trained sonographer uses ultrasound to measure your carotid artery layers during a 15-minute non-invasive scan. Results with physician interpretation arrive within 10 business days, showing arterial health status and risk levels.
Is CIMT covered by insurance?
Many major insurers and Medicare reimburse for CIMT testing in at-risk populations. The test is more cost-effective than alternatives like stress echos or EBCT while providing superior predictive accuracy for cardiovascular events.
How accurate is the testing?
Clinical studies show 98.6% accuracy in detecting cardiovascular events before they occur. Our standardized protocol with FDA-cleared equipment and biannual validation ensures consistent, reproducible results across all testing locations.
What makes CardioRisk different?
We provide turnkey solutions with no equipment investment required. Our patented protocols, university-validated quality controls, and physician support services create a seamless experience for medical practices and patients.
